磷酸化VEGFR2表达及阿帕替尼预后相关.pdf

Breast Cancer Res Treat (2014) 143:141–151 DOI 10.1007/s10549-013-2793-6 CLINICAL TRIAL Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy Minhao Fan • Jian Zhang • Zhonghua Wang • Biyun Wang • Qunlin Zhang • Chunlei Zheng • Ting Li • Chen Ni • Zhenhua Wu • Zhimin Shao • Xichun Hu Received: 12 October 2013 / Accepted: 23 November 2013 / Published online: 1 December 2013 Springer Science+Business Media New York 2013 Abstract The efficacy of anti-VEGF agents probably lies hand-foot skin reaction (HFSR), and proteinuria. Higher on VEGF-dependency. Apatinib, a specific tyrosine kinase tumor phosphorylated VEGFR2 (p-VEGFR2) expressions inhibitor that targets VEGF receptor 2, was assessed in (P = 0.001), higher baseline serum soluble VEGFR2 (P = patients with advanced breast cancer (ABC) (ClinicalTri- 0.031), hypertension (P = 0.011), and HFSR (P = 0.018) NC and NC. This substudy were significantly related to longer PFS, whereas hyperten- was to explore the potential biomarkers for VEGF-depen- sion (P = 0.002) and HFSR (P = 0.001) were also related to dency in apatinib-treated breast cancer. Eighty pretreated OS. Based on multivariate analysis, only p-VEGFR2 (adjus- patients received apatinib 750 or 500 mg/day orally in 4-week ted HR, 0.40; P = 0.013) and hypertension (adjusted HR, cycles. Circulating biomarkers were measured using a mul- 0.58; P = 0.038) were independent predictive factors for both tiplex assay, and tissue biomarkers were identified with PFS and clinical benefit rate. Apatinib had substantial anti- immunostaining. Baseline characteristics and adverse events tumor activity in ABC and manageable toxicity. p-VEGFR2 (AEs) were included in the analysi